文献速递真菌感染

泊沙康唑治疗囊性纤维化患者变应性支气管肺曲霉病

Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该回顾性分析纳入32例囊性纤维化合并变应性支气管肺曲霉病患者,评估曲霉特异性IgE及三唑类治疗药物监测。泊沙康唑组曲霉IgE显著下降,其他三唑类无此效果(P=0.026),且泊沙康唑血药浓度与IgE水平呈负相关。提示泊沙康唑在降低曲霉血清学反应方面优于对照唑类,治疗药物浓度达标者反应更佳。

要点

  • 泊沙康唑可显著降低囊性纤维化合并ABPA患者曲霉特异性IgE。
  • 其他三唑类未观察到曲霉IgE显著下降。
  • 泊沙康唑血药浓度与曲霉IgE水平呈负相关。

核心结论

  • 泊沙康唑在降低曲霉血清学反应方面优于对照唑类,且治疗药物浓度达标者反应更佳。

研究设计与样本

  • 回顾性分析32例囊性纤维化患者,评估曲霉特异性IgE及三唑类治疗药物监测。

主要发现

  • 泊沙康唑组曲霉IgE显著下降,其他三唑类无显著下降(P=0.026)。
  • 曲霉IgE水平与泊沙康唑治疗药物浓度呈负相关。

临床怎么用

  • 对于囊性纤维化合并ABPA患者,可考虑使用泊沙康唑并开展治疗药物监测以优化疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Allergic bronchopulmonary aspergillosis (ABPA) can accelerate lung function decline in patients with cystic fibrosis (CF). Antifungal medication can be used in addition to systemic corticosteroid treatment. PATIENTS AND METHODS: We evaluated Aspergillus-specific IgE and the use of therapeutic drug monitoring of triazoles in a retrospective analysis of 32 patients. RESULTS: There was a significant reduction in Aspergillus IgE with posaconazole but not with other triazoles (P = 0.026). Aspergillus IgE levels were inversely correlated with the therapeutic drug level of posaconazole. CONCLUSIONS: These data suggest that posaconazole is better than comparator azoles at decreasing serological response to Aspergillus and that this response was better with therapeutic levels of posaconazole.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Periselneris J, Nwankwo L, Schelenz S, et al. Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. J Antimicrob Chemother. 2019. PMID: 30805605. doi:10.1093/jac/dkz075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。